Compare · PETV vs RMD
PETV vs RMD
Side-by-side comparison of PetVivo Holdings Inc. (PETV) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PETV and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 2329.2x PETV ($12.4M).
- RMD has been more active in the news (7 items in the past 4 weeks vs 3 for PETV).
- RMD has more recent analyst coverage (25 ratings vs 1 for PETV).
- Company
- PetVivo Holdings Inc.
- ResMed Inc.
- Price
- $1.02-4.67%
- $198.99-1.86%
- Market cap
- $12.4M
- $28.86B
- 1M return
- -
- +2.60%
- 1Y return
- -
- -23.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 7
- Recent ratings
- 1
- 25
PetVivo Holdings Inc.
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PETV
- PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
- SEC Form 10-K filed by PetVivo Holdings Inc.
- PetVivo Reports Financial and Operational Results for Fiscal 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- PetVivo Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
- PetVivo Holdings Announces Transformative Acquisition Of PiezoBioMembrane To Build a Leading Functional Biomaterials Platform
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
- PetVivo Holdings, Inc. to Present at the Life Sciences Investor Forum on June 24th
- PetVivo Holdings, Inc. to Host Virtual Investor Event
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)